SCHEMBL461340

SCHEMBL461340

NSC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11098163 0.70
SCHEMBL7158952 0.70
SCHEMBL181825 0.70
SCHEMBL3189499 0.67 CA1 (0.33)
SCHEMBL2274959 0.67
Bicarbonate SCHEMBL5502655 0.67
SCHEMBL130293 0.65
SCHEMBL2910940 0.65
SCHEMBL4562572 0.65
SCHEMBL8180839 0.63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111934016-B Non-aqueous electrolyte of lithium ion battery and lithium ion battery containing non-aqueous electrolyte 珠海市赛纬电子材料股份有限公司 2023-05-12 CN claimed
CN-111934016-A Non-aqueous electrolyte of lithium ion battery and lithium ion battery containing non-aqueous electrolyte 珠海市赛纬电子材料股份有限公司 2020-11-13 CN claimed
EP-2209776-A1 AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDER Bayer Schering Pharma AG (DE) 2010-07-28 EP claimed
EP-2084154-A1 AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR TREATMENT OF THROMBOEMBOLIC DISORDERS Bayer Schering Pharma Aktiengesellschaft (DE) 2009-08-05 EP claimed
EP-1471921-B1 COUNTERACTING BIOPROSTHETIC CALCIFICATION PHILADELPHIA CHILDREN HOSPITAL (US) 2009-03-11 EP claimed
EP-1268561-B1 METHOD FOR PRODUCING POLYMERS BASF SE (DE) 2009-01-28 EP claimed
WO-2009007026-A1 AMINOACYL PRODRUGS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-15 WO claimed
WO-2008022786-A1 AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR TREATMENT OF THROMBOEMBOLIC DISORDERS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-02-28 WO claimed
US-6809165-B2 Method for producing polymers BASF AKTIENGESELLSCHAFT (DE) 2004-10-26 US claimed
US-20030073793-A1 Method for producing polymers BASF AKTIENGESELLSCHAFT (DE) 2003-04-17 US claimed
EP-3643713-B1 HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2025-07-30 EP disclosed
US-20250101015-A1 HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2025-03-27 US disclosed
US-20250084076-A1 HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2025-03-13 US disclosed
US-12172993-B2 Heterocyclic kinase inhibitors and uses thereof IOMX THERAPEUTICS AG (DE) 2024-12-24 US disclosed
CN-117015526-A Aryl sulfonamides as orexin receptor agonists 研究三角协会 2023-11-07 CN disclosed
US-5686382-A Thermal recording structure and method RICOH COMPANY, LTD. (JP) 1997-11-11 US disclosed
CN-1132505-A Amidine derivatives with nitric oxide synthetase activities ASTERA CO (SE) 1996-10-02 CN disclosed
US-5169992-A Bisphenol A production using acidic clay catalysts TEXACO CHEMICAL COMPANY (US) 1992-12-08 US disclosed
US-4618669-A FOR CELL INJURIES CAUSED BY ACTIVE OXYGEN METABOLITES A. NATTERMANN & CIE GMBH (DE) 1986-10-21 US disclosed
EP-0004711-A2 Process for the cross-linking of polymers Vulnax International Limited (GB) 1979-10-17 EP disclosed